Fig. 3From: Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center studySubgroup analysis of PFS by patient characteristics. Forest plots of PFS evaluated in subgroups depending on the clinicopathological featuresBack to article page